Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated
interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants